L A Emtage - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

L A Emtage

Showing results (1-10 of 11) with videos related to

Pageof 2

Sort By:

British Journal of Urology|July 1, 1994

A renal epidermoid cystL A Emtage, C Allen

Lancet (London, England)|February 24, 1990

Association between serum albumin and mortality from prostatic cancerL A Emtage, G Blackledge

Journal of the Royal College of Surgeons of Edinburgh|August 1, 1985

Four primary carcinomas of the large bowel in a young manL A Emtage, M D Middleton

British Journal of Urology|June 1, 1989

Androgen and oestrogen receptor status in benign and neoplastic prostate disease. Study of prevalence and influence on time to progression and survival in prostate cancer treated by hormone manipulationL A Emtage, P J Dunn, A D Rowse

British Journal of Urology|December 1, 1987

The role of prostate specific antigen in the baseline assessment of patients undergoing hormone therapy for advanced prostate cancerL A Emtage, P W Lewis, G R Blackledge

Journal of Clinical Pathology|November 1, 1988

HMFG-2 as a prognostic indicator in superficial bladder cancerI G Conn, J Crocker, L A Emtage, et al.

American Journal of Clinical Oncology|January 1, 1988

Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer. The West Midlands Urology Research GroupL A Emtage, C Trethowan, C Hilton, et al.

European Journal of Cancer (Oxford, England : 1990)|March 1, 1990

Haemostatic changes during hormone manipulation in advanced prostate cancer: a comparison of DES 3 mg/day and goserelin 3.6 mg/monthL A Emtage, J George, B J Boughton, et al.

British Journal of Urology|June 1, 1992

Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancerB Waymont, T H Lynch, J A Dunn, et al.

Progress in Clinical and Biological Research|January 1, 1989

A phase III open randomized study of Zoladex 3.6 mg depot vs. DES 3 mg per day in untreated advanced prostate cancer: a West Midlands Urological Research Group StudyL A Emtage, C Trethowan, K Kelly, et al.

Pageof 2

Search research articles

Showing results (1-10 of 11) with videos related to

Sort By:

Pageof 2

British Journal of Urology|July 1, 1994

A renal epidermoid cystL A Emtage, C Allen

Lancet (London, England)|February 24, 1990

Association between serum albumin and mortality from prostatic cancerL A Emtage, G Blackledge

Journal of the Royal College of Surgeons of Edinburgh|August 1, 1985

Four primary carcinomas of the large bowel in a young manL A Emtage, M D Middleton

British Journal of Urology|June 1, 1989

Androgen and oestrogen receptor status in benign and neoplastic prostate disease. Study of prevalence and influence on time to progression and survival in prostate cancer treated by hormone manipulationL A Emtage, P J Dunn, A D Rowse

British Journal of Urology|December 1, 1987

The role of prostate specific antigen in the baseline assessment of patients undergoing hormone therapy for advanced prostate cancerL A Emtage, P W Lewis, G R Blackledge

Journal of Clinical Pathology|November 1, 1988

HMFG-2 as a prognostic indicator in superficial bladder cancerI G Conn, J Crocker, L A Emtage, et al.

American Journal of Clinical Oncology|January 1, 1988

Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer. The West Midlands Urology Research GroupL A Emtage, C Trethowan, C Hilton, et al.

European Journal of Cancer (Oxford, England : 1990)|March 1, 1990

Haemostatic changes during hormone manipulation in advanced prostate cancer: a comparison of DES 3 mg/day and goserelin 3.6 mg/monthL A Emtage, J George, B J Boughton, et al.

British Journal of Urology|June 1, 1992

Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancerB Waymont, T H Lynch, J A Dunn, et al.

Progress in Clinical and Biological Research|January 1, 1989

A phase III open randomized study of Zoladex 3.6 mg depot vs. DES 3 mg per day in untreated advanced prostate cancer: a West Midlands Urological Research Group StudyL A Emtage, C Trethowan, K Kelly, et al.

Pageof 2